SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, is collaborating with Clearmind Medicine on a patent application filed in Hong Kong for a novel MEAI‑PEA combination therapy aimed at treating major depressive disorder.

The filing describes a non‑hallucinogenic neuroplastogen approach combining Clearmind’s MEAI with Palmitoylethanolamide (PEA) sourced by NeuroThera. According to the filing context, the therapy targets depression, which affects > 332 million people worldwide per WHO (Aug 2025).

Positive

• Controlling interest of ~75% in NeuroThera
• Patent application filed in Hong Kong for MEAI‑PEA combination therapy
• Targets major depressive disorder affecting >332 million people (WHO, Aug 2025)

Negative

• Patent application status is pending; grant is not guaranteed

Key Figures

NeuroThera ownership: approximately 75% Depression prevalence: more than 332 million people

2 metrics

NeuroThera ownership approximately 75% SciSparc’s controlling interest in NeuroThera Labs

Depression prevalence more than 332 million people Global burden of depression per WHO August 2025 article

Market Reality Check

Price: $4.36 Vol: Volume 52,256 vs 20-day a...

low vol

$4.36 Last Close

Volume Volume 52,256 vs 20-day average 246,054 (relative volume 0.21) shows subdued trading ahead of this news. low

Technical Shares at $4.36 were trading below the 200-day MA of $31.33, and about 95.39% below the 52-week high.

Peers on Argus

SPRC was down 7.82% while close peers showed mixed single-day moves, from -29.14...

SPRC was down 7.82% while close peers showed mixed single-day moves, from -29.14% (UBX) to +2.89% (REVB), indicating stock-specific dynamics rather than a unified biotech sector move.

Historical Context

5 past events · Latest: Mar 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 12	Collaboration patent news	Positive	+22.9%	International patent publication for MEAI–PEA combo in weight loss and MASLD.
Mar 10	Subsidiary acquisition deal	Positive	-28.3%	NeuroThera to acquire about 54.01% of CliniQuantum via share issuance.
Mar 02	Reverse share split	Neutral	-9.9%	1-for-9 reverse split to reduce outstanding shares to roughly 565,500.
Feb 02	U.S. patent grant	Positive	+0.1%	U.S. patent for antimicrobial–cannabinoid tech targeting resistant pathogens like MRSA.
Jan 26	IP portfolio acquisition	Positive	-7.9%	Acquisition of MUSE™ GERD device IP to pursue commercialization and partnerships.

Pattern Detected

Recent positive corporate and IP developments have often seen mixed-to-negative next-day price reactions.

Recent Company History

Over the last few months, SciSparc reported several strategic steps: multiple patents via majority-owned NeuroThera Labs, acquisitions such as the CliniQuantum stake and an IP portfolio for the MUSE™ GERD device, and a 1-for-9 reverse split effective March 4, 2026. Same-day and next-day price reactions were volatile, including moves of +22.86%, -28.34%, and -9.87%. Today’s patent-related news on depression therapy fits an ongoing pattern of IP expansion amid a fragile share price backdrop.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-17

An effective Form F-3 filed on Feb 17, 2026 registers up to 23,037,624 ordinary shares for resale by existing investors tied to a convertible note and warrants. The filing highlights risks from dilution, resale overhang, and volatility, along with existing Nasdaq equity compliance challenges and going-concern language in past financials.

Market Pulse Summary

This announcement highlights a new patent application in Hong Kong for an MEAI‑PEA combination thera...

Analysis

This announcement highlights a new patent application in Hong Kong for an MEAI‑PEA combination therapy targeting major depressive disorder, leveraging SciSparc’s roughly 75% stake in NeuroThera Labs and its collaboration with Clearmind. It builds on a series of recent IP and transaction updates. Investors may watch for future clinical data, regulatory milestones, and how ongoing financing and resale registrations affect capitalization and execution capacity.

Key Terms

central nervous system (cns), major depressive disorder (mdd), neuroplastogen

3 terms

central nervous system (cns) medical

"a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders"

The central nervous system (CNS) is the part of the body that includes the brain and spinal cord, acting as the control center for processing information and directing actions. It is essential for coordinating all bodily functions, from movement to thinking. For investors, understanding the CNS is important because it illustrates how complex systems—like markets or organizations—rely on core components to operate smoothly.

major depressive disorder (mdd) medical

"designed to treat major depressive disorder (MDD)"

Major depressive disorder (MDD) is a clinical mental-health condition characterized by persistent low mood, loss of interest in usual activities, and changes in sleep, appetite, energy, and concentration that significantly impair daily functioning for weeks or longer. It matters to investors because MDD drives healthcare spending, shapes demand for treatments, affects workforce productivity and absenteeism, and influences the commercial and regulatory prospects of companies developing therapies—like a chronic engine problem that reduces output and raises repair costs.

neuroplastogen medical

"MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression"

A neuroplastogen is a drug or compound designed to boost the brain’s ability to rewire and form new connections, enhancing recovery or adaptation after injury, stress, or disease. For investors, these molecules matter because they target underlying brain repair processes rather than just masking symptoms, offering the potential for durable benefits in conditions like depression, neurodegeneration, or cognitive decline—akin to giving a tired garden fresh tools to regrow and reshape itself.

AI-generated analysis. Not financial advice.

TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department  in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).

This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera.

The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025 Given the anticipated mechanism of action, this therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) and other conventional options.

About SciSparc Ltd. (Nasdaq: SPRC):

The Company, through its majority-owned subsidiary NeuroThera Labs Inc., engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera Labs Inc., are currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of ASD and status epilepticus. The Company, through NeuroThera Labs Inc., also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.

About NeuroThera Labs Inc.

NeuroThera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential benefits and advantages from the therapy under the patent, and that therapy could provide a more accessible, safer, and affordable alternative to existing antidepressants, including SSRIs and other conventional options. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, as amended, filed with the SEC on April 24, 2025, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

What did SciSparc (SPRC) announce on March 16, 2026 about NeuroThera?

SciSparc announced NeuroThera’s collaboration with Clearmind and a patent application filed in Hong Kong for an MEAI‑PEA therapy. According to SciSparc, SciSparc holds approximately 75% controlling interest in NeuroThera.

What is the MEAI‑PEA therapy mentioned by SciSparc (SPRC)?

The MEAI‑PEA therapy combines Clearmind’s proprietary MEAI with Palmitoylethanolamide (PEA) sourced by NeuroThera. According to SciSparc, it is presented as a non‑hallucinogenic neuroplastogen approach for MDD.

Where was the patent application for the MEAI‑PEA combination filed for SciSparc (SPRC)?

The patent application was filed with the Intellectual Property Department in Hong Kong, China. According to SciSparc, Clearmind submitted the filing as part of the NeuroThera collaboration.

How many people could the SciSparc (SPRC) MEAI‑PEA therapy potentially address?

The therapy targets major depressive disorder, which the WHO estimated affects >332 million people globally (Aug 2025). According to SciSparc, that figure frames the potential patient population.

Does SciSparc (SPRC) say the MEAI‑PEA patent is approved?

No—SciSparc reports a patent application filing, not a granted patent. According to SciSparc, the application is pending and subject to examination and approval processes.

What is SciSparc’s ownership stake in NeuroThera as disclosed on March 16, 2026?

SciSparc holds a controlling interest of approximately 75% in NeuroThera. According to SciSparc, this stake gives it majority exposure to NeuroThera’s clinical programs.